Nuron Biotech Inc.

Founded by veterans of Pfizer, Nuron Biotech Inc. is developing a recombinant human interferon beta-1 free of human serum albumin and the aggregates that set off an immune response. Thus the start-up's lead candidate should not lose effectiveness or have the tolerability issues that plague existing interferon beta drugs. The company will move its agent directly into Phase III clinical trials in Europe this year.